학술

Prevalence and genotype distribution of human papillomavirus in women from northern provinces of Lao People’s Democratic Republic, 2018–2019

PLOS ONE
CC BY
이 매체는 공공·자유 라이선스로 본문을 직접 표시합니다.

Figures
Abstract
Background
Cervical cancer is a frequent cause of morbidity and mortality in women worldwide and strongly linked to the presence of high-risk (HR) human papillomavirus (HPV) genotypes. The present study aimed to determine HPV prevalence and genotypes and their relationship with cytology results in Lao women.
Methods
Between October 2018 and February 2019, a total of 1302 asymptomatic women (mean age 37.4 years, range 18–76) from Xiengkhouang, Luangprabang, Oudomxay and Huaphan provinces were invited to answer a questionnaire, and cervical cells were collected for cytology and a swab for PCR and AnyplexTM II HPV-HR detection.
Results
Overall, 114 of 1268 women with evaluable samples (9.0%) had abnormal cytology and three (0.2%) had cervical cancer. AnyplexTM II HPV-HR kit detected 256 positives among 1184 participants (21.6%), with types 52, 58 and 16 being the most prevalent HR genotypes (20.4%, 12.8% and 11.7%, respectively). Multivariable analysis showed that participants aged ≥ 40 years (OR: 1.6; 95% CI: 1.1–2.4, p = 0.015) and those living in Luangprabang province (OR: 1.9; 95% CI: 1.1–3.2, p = 0.02) had a higher likelihood of abnormal cytology compared to younger women and those residing in Huaphan. Single/divorced/widow women had a higher probability of HPV detection compared to married women (OR: 2.3; 95% CI: 1.5–3.7, p < 0.001).
Citation: Khounvisith V, Samountry B, van Beek J, Sausy A, Brunnhoefer R, Vongphachanh B, et al. (2026) Prevalence and genotype distribution of human papillomavirus in women from northern provinces of Lao People’s Democratic Republic, 2018–2019. PLoS One 21(11): e0363215. https://doi.org/10.1371/journal.pone.0363215
Editor: Cecilia Acuti Martellucci, University of Bologna: Universita di Bologna, ITALY
Received: July 8, 2026; Accepted: November 5, 2026; Published: November 20, 2026
Copyright: © 2026 Khounvisith et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Data Availability: The minimal anonymized dataset necessary of this study is provided as Supporting Information. Data potentially identify individual participants are not publicly available because of ethical and confidentiality restrictions imposed by the National Ethics Committee for Health Research (NECHR), Lao PDR.
Funding: Ministry of Foreign and European Affairs, Defence, Development Cooperation and Foreign Trade (“PaReCIDS II). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
Abbreviations: ASCUS, Atypical squamous of undetermined significance; CIN, Cervical Intraepithelial Neoplasia; HPV, Human papillomavirus; HR-HPV, High Risk-Human papillomavirus; HSIL, High grade squamous intraepithelial lesion; Lao PDR, Lao People’s Democratic Republic; LBC, Liquid Based Cytology; LR-HPV, Low Risk- Human papillomavirus; LSIL, Low-grade squamous intraepithelial lesion; NECHR, National Ethics Committee for Health Research; OR, Odds ratio; PCR, Polymerase Chain Reaction; SCC, Squamous cell carcinoma; UHS, University of Health Science; VIA, Visual Inspection with Acetic acid
Introduction
Human papillomavirus (HPV) belongs to the Papillomaviridae family and at least 150 genotypes are known. More than 40 genotypes can be transmitted by sexual contact via the skin and mucous membranes. The HPV genotypes can be divided into low-risk HPV (LR-HPV) (types 6, 11, 40, 42, 43, 44, 53, 54, 61, 72, 73, 81) and high-risk HPV (HR-HPV) (types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 68) based on the associated risk of cervical cancer [1,2]. Cervical cancer is the fourth most common cancer in women globally. In 2020, it was estimated that every year 600,000 new cervical cancer cases are detected and more than half of them die as a result of the disease [3]. About 85% of cervical cancer deaths are thought to occur in developing countries [4]. Worldwide, HPV 16 and 18 are linked with 70–75% of cervical cancer cases and 50% of cervical intraepithelial neoplasia grade 3 (CIN3), a precancerous condition [5]. Studies in healthy young women from Japan and China have reported that the most prevalent HR-HPV types are 16 and 52 [6,7]. Risk factors for infection with HR-HPV include, e.g., early age of first sexual contact, high lifetime number of sexual partners and many years of oral contraceptive use [8–10].
Cervical cancer screening consists of visual inspection with acetic acid (VIA) or cervical cytology (e.g., Pap test) and molecular screening is used to detect HR-HPV subtypes. VIA is a primary screening in low- and middle-income countries since it is easy to perform and not expensive [11]. However, sensitivity and specificity are suboptimal [12]. The Pap test is used to detect precancerous lesions and consists of collecting cervical cells, fixing them on a slide and examining them under a microscope. Although in principle easy to perform, the quantity and/or quality of the collected cells are sometimes inappropriate for a proper evaluation of the specimen. In addition, the sensitivity to detect precancerous lesions has been reported to be only around 55%, while a high specificity of 96.8% was found [13]. Liquid-based cytology (LBC) is an alternative method using a brush or spatula to collect material, which is then transferred into a vial containing a fixative liquid. Some studies showed that the low-grade cytologically abnormal stages are more often detected with LBC [14], which was reported to have a sensitivity and specificity of 94.6% and 94.1% respectively [13]. LBC is thought to reduce false negative results due to low-quality smears and is fast, but expensive [15]. Cytology and histology results are observer-dependent and especially in low-and-middle-income countries, including Lao People’s Democratic Republic (Lao PDR), trained pathologists are rare, which limits diagnostic capacity and may delay result interpretation.
The Lao population comprises about 2.26 million women aged 15 years and older, who are at risk of developing cervical cancer [16]. Since 2020, Lao PDR has implemented a national HPV vaccination program, which is largely school-based and targets adolescent girls aged 10–14 years. Currently the quadrivalent vaccine against HPV types 6, 11, 16 and 18, the most common causes of cervical cancer, is used [17]. In 2021, an estimated 300 cases of cervical cancer occurred in Lao PDR, resulting in the classification of cervical cancer as the fourth most frequent cancer in Lao women and the third most common in women between 15 and 44 years [16]. A study conducted in 2008 showed that 58% of Lao women had heard of cervical cancer and 38% considered themselves to be at risk, but only 5% had done a Pap test [18]. Another study from 2009 conducted in 1922 asymptomatic women from 3 provinces (Vientiane Capital, Luangprabang and Champasack province) found an HR-HPV prevalence of 11% in women visiting gynaecology departments with the most common types being HPV 33, 52 and 58 (3%), HPV 16 (2%) and HPV 18/45 (1%) [8]. However, that study did not determine the associations between HPV type and cervical cytology. In 2017, a study among asymptomatic healthy females in Vientiane capital found that 9.3% (132/1422) had abnormal cytology and 47.7% of these (63/132) were HR-HPV positive. The most common types were HPV 16 (20.5%) and HPV 58 (9.1%) [19].
This study aimed to determine the HPV prevalence, genotype distribution, and risk factors in asymptomatic women in 4 provinces in Lao PDR in order to inform future screening and vaccination strategies and to monitor control efforts. In addition, and due to so far limited information, the relationship between cytology and HPV prevalence and types was investigated.
Methodology
Study population
Sample and data collection
DNA extraction
HPV DNA was extracted from cervical cells by using QIAamp DNA kits according to the manufacturer’s instructions [23]. DNA was eluted in 100 µl of AF buffer and then stored at −20°C. An extraction control (hepatitis B virus DNA positive serum) was used to assess extraction quality of each run. Two different HPV detection methods were used for sample screening, namely a more affordable and broad-range HPV in-house assay and a commercial assay for HR detection and genotype determination requiring a specific platform to compare performance and suitability for routine screening of asymptomatic women.
Specifically, DNA amplification was done by in-house PCR using GP5 + /GP6 + primers [24], generating an amplicon of 150 bp. For each PCR, positive controls (extracted DNA from HPV16 and HPV18 virus culture) and a negative control (water) were included. PCR products were analysed by gel electrophoresis on a 1% agarose gel. Samples were considered HPV-positive when the PCR product of the expected size was visible on the gel.
In addition, all samples were tested with the Anyplex™ II HPV HR Detection kit (Seegene) according to the manufacturer’s manual [25] to identify HPV-HR genotypes.
Data analysis
Data were analysed by STATA version 14. Descriptive analysis included independent variables such as age, ethnicity, occupation, education, marital status, income, age at first sexual contact, number of sexual partners, previous cervical screening, vaginal infection, smoking and use of oral contraceptives. Chi-square or Fisher’s exact tests were done for bivariate analysis using independent variables and HPV genotype in relation to cytology, Anyplex TM II HPV HR and PCR results. Variables with a p-value lower than 0.2 were included in the model. Variables considered potential confounders, regardless of p-value, such as province, age, ethnicity, occupation, education, marital status, number of sexual partners and vaginal infection were also incorporated into the regression analysis. All associations were evaluated for significance at p < 0.05.
Ethical considerations
Results
Participant characteristics
A total of 1302 women were included in this study with a mean age of 37.4 years (standard deviation (SD) 9.1 years, range 18–76 years). Most women (n = 1127, 86.6%) belonged to the Lao-Loum ethnicity. About half (n = 655, 50.3%) were government staff and 23% (n = 300) were shop owners. Overall, 410 (31.5%) women completed secondary high school and 264 (20.3%) had a bachelor degree. The vast majority (n = 1197, 91.9%) were married.
More than half of the women (n = 713, 54.8%) had their first sexual contact at the age of 20–25 years and 230 (17.7%) indicated to have had more than one sexual partner. Only 404 (31%) participants reported that they had a previous cervical screening (n = 393, 30.2% had a Pap test and n = 11, 0.8% a VIA). About one quarter of the women (n = 328, 25.2%) reported that they have had vaginal infection or sexually transmitted diseases (STD) and candidiasis was most often named (n = 247, 75.8%). A total of 1049 (80.6%) women had used contraceptives, with the pill being most often used (n = 375, 35.8%) (Table 1).
Cytological examination
Pap test results based on the Bethesda system showed that 1151 of the 1268 women with evaluable swabs (90.8%; 34 specimens of low quality had to be excluded) had normal cytology. A total of 114 women (9.0%) had an abnormal cytology and three (0.2%) had cervical cancer (squamous cell carcinoma and adenocarcinoma) (Table 2).
Anyplex TM II HPV HR detection
Of the 1302 samples tested, 118 yielded invalid (n = 24) or borderline (n = 94) results and had to be excluded. Overall, 256 of the remaining 1184 (21.6%) samples were positive and all 14 HR-HPV types included in the assay were detected (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68). HR-HPV 52, 58 and 16 were the most prevalent with 20.4%, 12.8% and 11.7%, respectively (Fig 1).
The numbers above the bars indicate the total number of detections by Anyplex PCR, including multiple detections in a single sample (100 samples were positive for more than one genotype).
In-house PCR results and comparison to Anyplex TM II HPV HR detection.
Of the 1302 samples tested, 277 (21.3%) were PCR-positive and 1025 (78.7%) were negative. Overall, 41 samples were positive by PCR, but negative using Anyplex, while 37 samples were positive by Anyplex, but negative by PCR (8 different HPV types were concerned, n = 22 were identified as HPV 52). Of the 24 samples classified as invalid after Anyplex testing, 7 were positive and 17 were negative by PCR. The 94 Anyplex borderline samples yielded 10 positive and 84 negative results by in-house PCR.
Comparison between cytology and DNA detection results
A total of 23 samples from women with abnormal cytology were positive in both PCR and Anyplex, while 4 were positive only by Anyplex and 8 only by PCR. Of the 3 samples from women with cancer, 1 was PCR negative and invalid by Anyplex, while the other two were positive with both methods. Among the 114 women with abnormal cytology, 83 had a negative result by in-house PCR, while Anyplex yielded 71 negative, 5 invalid and 11 borderline results (Table 3). Among the 1151 women with normal cytology, 234 were positive by PCR and 217 by Anyplex (Table 4). Of the 34 samples with invalid cytology, 10 and 8 were tested positive by PCR and by Anyplex, respectively (Table 3).
Cytology and HR-HPV genotype.
Overall, 14 different HR-HPV genotypes were found in participants with normal cytology. The three most common types were HPV 52, HPV 58 and HPV 16 (14.8%, 9.2% and 7.4% respectively). Moreover, 37.3% (81/217) of the women with normal cytology were positive for at least two HR-HPV types (Fig 2).
*There were 48 unique combinations, not detailed here. **Three genotypes: 66/16/18, 52/68/3, 16/39/52, 66/51/31, 58/59/18, 66/52/56, 51/16/68, 58/39/68, 66/16/33, 52/18/68, 66/16/68, 58/39/18, 66/58/52, 58/39/18, 35/68/31, 51/16/52, 59/18/68, 58/33/52 and 58/16/52. ***Four genotypes: 58/51/52/18, 58/51/39/52, 51/39/52/68, 51/39/56/68, 66/51/52/31 and 58/16/39/56. ****Five genotypes: 58/51/52/28/68 and 45/58/16/18/31.
HR-HPV genotypes associated with abnormal cytology were HPV 16, 18, 33, 39, 51, 52, 58 and 68. HPV 52 was the most common (n = 6/27, 22.2%), followed by HPV 58 (n = 4/27, 14.8%) and HPV 16 and 33 with 2 samples each. In addition, 22.2% of the women with abnormal cytology were positive for two HR-HPV types, while infections with more types were less common (Fig 3).
* Two genotypes: 16/33, 51/39, 33/52, 18/16, 51/16, 16/45. **Four genotypes: 58/39/68/52. ***Five genotypes: 58/59/16/39/52 and 58/45/39/31/52. HR-HPV genotypes 16 and 33, respectively, were detected in the two cancer patients with an Anyplex positive result.
Bivariate analysis for Cytology, Anyplex and in-house PCR results
Due to the low number of cancer patients (0.2% of all women with analysable cytology results), we combined that category with the abnormal cytology category for the purpose of bivariate and multivariable analyses (thus, “abnormal cytology” comprises both categories in these sections). After analysis, two variables, namely province and age, were significant (Table 4). Women aged ≥ 40 had a higher probability of having abnormal cytology than younger women (OR: 1.8, 95% CI 1.2–2.7, p = 0.002), as did women living in Luangprabang province compared to women living in another province (OR: 2.1, 95% CI 1.3–3.6, p = 0.002).
Four variables were statistically significant for the Anyplex results, comparing positives to all other results: age, occupation, marital status and number of sexual partners. Women aged ≥ 40 had a lower probability of being HPV DNA positive than younger women (OR: 0.7, 95% CI 0.5–1.0, p = 0.04). Moreover, office staff and housewives/farmers/commerce staff had a lower probability of being HPV DNA positive than students (OR: 0.2%, 95% 0.1–0.5 CI, p < 0.001). Single/divorced/widowed women and those who had sex with more than one partner had a higher chance of being HPV DNA positive than women with another marital status and women with only one sexual partner (OR: 2.5, 95% CI 95% CI 1.6–3.8, p < 0.001 and OR: 1.6, 95% CI 1.2–2.2, p = 0.005, respectively).
For the PCR results, three variables were significant: occupation, marital status and number of sexual partners. Office staff had a lower probability of being HPV positive than students (OR: 0.4, 95% CI 0.1–0.9, p = 0.04). Single/divorced/widowed women had a higher likelihood of being HPV DNA positive (OR: 2.2, 95% CI 1.4–3.5, p=<0.001) as did women who had sex with more than one partner (OR: 1.4, 95% CI 1.0–2.0, p = 0.05).
Multivariable analysis
In multivariable analysis, the final model included 8 variables: province, age, ethnicity, occupation, highest education, marital status, number of sexual partners and vaginal infection with abnormal cytology, Anyplex and PCR. Participants aged ≥ 40 years (OR: 1.6; 95% CI: 1.1–2.4, p = 0.015) and those living in Luangprabang province (OR: 1.9; 95% CI: 1.1–3.2, p = 0.02) exhibited a higher likelihood of abnormal cytology compared to younger women and those residing in Huaphan, while women living in Oudomxay had a lower likelihood (OR: 0.5, 95%CI: 0.3–1.0, p = 0.04).
For HPV detection by Anyplex, two variables were statistically significant: single/divorced/widowed women had a higher probability of HPV detection compared to married women (OR: 2.3; 95% CI: 1.5–3.7, p < 0.001). Women aged ≥ 40 years showed a lower probability of HPV infection compared to younger women (OR: 0.7; 95% CI: 0.5–1.0, p = 0.05).
For HPV infection detected by PCR, only one variable was significant: single/divorced/widowed women demonstrated a higher probability of HPV infection compared to married women (OR: 2.1; 95% CI: 1.3–3.4, p = 0.004) (Table 5).
Discussion
Lao women tend to have cervical cancer check-ups only when they are symptomatic, possibly due to a low awareness of sexually transmissible infections [18]. Population screening is not a routine practice and is restricted to Central and some Provincial Hospitals [8], and cervical cancer treatment options are limited in Lao PDR.
The overall prevalence of women with abnormal cytology observed in our study (9.0% in 1268 asymptomatic women) was similar to the 9.3% observed in 1422 women recruited in six different hospitals in Vientiane capital in 2012 [19]. However, the rate of women with HPV DNA detection of about 21% was much lower than the previously reported 47.7% (63/132) [19]. This discrepancy might be linked to a different methodology, the different age range of 30–54 years, and the restricted geographical setting of the previous study, with all six district hospitals being located in Vientiane capital. Although we have excluded all Anyplex invalid and borderline results and might thus have underestimated the true prevalence of HPV in the study population, the prevalence of HPV positives was similar by in-house PCR. While the in-house PCR is meant for broad-spectrum HPV DNA detection, the Anyplex Multiplex PCR is designed for simultaneous detection and identification of 14 HR-HPV genotypes in a single reaction. Discrepancies between the two detection methods could therefore be due to differences in the targeted HPV types, as well as the sensitivity and specificity to detect these HPV types. Our results did not allow us to conclude whether the cheaper and more easily accessible in-house PCR is a suitable alternative to the commercial assay and future studies might be needed to determine the best approach in low-resource settings such as Lao PDR.
The HR-HPV prevalence in our study (21.6%) was higher than that reported among Lao women in a previous study (9.3%) [19]. Regarding genotype distribution, HPV16, HPV52, and HPV58 were among the most frequently detected types in our study, which is comparable to findings from East Asia, where HPV52 and HPV58 have been reported at relatively high frequencies [26].
HPV types 52, 58 and 16 were most commonly detected, both among participants with normal and with abnormal cytology, confirming previous reports from Lao PDR [8] and probably reflecting different disease progression stages among participants [8,19]. These findings clearly advocate for the introduction of the nonavalent vaccine, which also includes components against types 52 and 58 [17].
Most women with abnormal cytology were HPV DNA negative, suggesting limitations of cytology as a standalone diagnostic tool and/or the presence of non-HPV-related causes for abnormal cytology, such as inflammation, hormone use, other infections or technical issues during sample processing for cytology [27]. Also, false negative PCR results due to inappropriate sample collection, transportation or storage might be an explanation, possibly reflected already by the 118 samples classified as invalid in the Anyplex assay. Further investigations may be needed to better understand these discrepancies.
The presence of nearly 220 patients with detectable HR-HPV types but normal cytology suggests a high future burden of cervical cancer. This observation underscores the need for improved and extended screening and diagnostic strategies, including, for example, an initial donor-financed national screening program to better understand future target (age) groups. Infection with multiple HR-HPV types among more than one-third of these women suggests a higher risk of cervical cancer development, more severe disease, or faster progression [28,29]. Long-term follow-up and additional research are needed to better estimate and ideally reduce the future burden of cervical cancer in Lao PDR.
In our study, women aged more than 40 years had a nearly twice as high risk of having abnormal cytology as younger women, but a lower probability of HPV detection, possibly because of the presence of other causes for abnormal cytology and cervical cancer, such as age-related cervical atrophy, inflammation, etc. [30,31] and/or false negative PCR results. The higher prevalence of women with abnormal cytology in Luangprabang is consistent with findings from a prior study [8] and might be related to the fact that, as a world heritage site, Luangprabang is a tourist hub with connections to different bordering countries [32], increasing the risk of HPV exposure and transmission. Interestingly, women from Oudomxay province next to Luangprabang province [33] had a lower likelihood of abnormal cytology for unknown reasons.
Married women had a lower likelihood of HPV DNA positivity, and both married and older women had lower likelihoods of being positive for HR-HPV types included in the Anyplex test, possibly linked to a different sexual behaviour. In fact, it was more common to refrain from having sexual intercourse before marriage at the time when these women were young, while nowadays women tend to have their first sexual intercourse at an earlier age and have multiple partners [34]. This might also explain why many 15–29 year-old women reported previous infection with sexually transmitted diseases [8].
Conclusion
In conclusion, HPV 52, 58 and 16 were the most prevalent high-risk types among women with normal and abnormal cytology in northern Lao PDR, clearly advocating for the introduction of the nonavalent vaccine. Infections with multiple HR-HPV types among asymptomatic women suggested a high future burden of cervical cancer in northern Lao PDR. While the differences observed for the three screening methods deserve further investigation, implementation of early screening, particularly of women aged ≥ 40 years, and regular follow-up of PCR-positive women is essential to effectively reduce the incidence and severity of cervical cancer in northern Lao PDR.
Supporting information
S1 File. Supporting information questionnaire.
https://doi.org/10.1371/journal.pone.0363215.s001
(PDF)
S2 File. Inclusivity in global research quest.
https://doi.org/10.1371/journal.pone.0363215.s002
(DOCX)
Acknowledgments
We would like to express our gratitude to the University of Health Science for their collaboration including for sample collection. We thank the Laboratoire National de Santé, Dudelange, Grand-Duchy of Luxembourg for allowing and conducting Anyplex testing at their facilities. We also acknowledge Lisa Hefele for her statistical support and Bounta Vongphachanh from the LaoLuxLab for her support with sample collection and laboratory testing. Additionally, we would like to thank the staff of the provincial hospitals, the study participants and heads of village for their participation and support. Lastly, we would like to acknowledge the administration and management of the Institut Pasteur du Laos for their support when conducting the study.
References
- 1. Yuanyue L, Baloch Z, Yasmeen N, Tao Y, Xiaomei W, Xueshan X. The distribution of human papillomavirus genotypes in cervical cancer and intraepithelial neoplasia lesions among Chinese women in Yunnan Province. J Infect Public Health. 2018;11(1):105–10. pmid:28697900
- 2. Zhou XH, Shi YF, Wang LJ, Liu M, Li F. Distribution Characteristics of Human Papillomavirus Infection: A Study Based on Data from Physical Examination. Asian Pac J Cancer Prev. 2017;18(7):1875–9. pmid:28749128
- 3.
Bruni L, Albero G, Serrano B, Mena M, Collado J, Gómez D. Human Papillomavirus and Related Diseases Report. 2023. www.hpvcentre.net
- 4. Nour NM. Cervical Cancer: A Preventable Death. Rev Obstet Gynecol. 2009;2:240.
- 5. de Martel C, Plummer M, Vignat J, Franceschi S. Worldwide burden of cancer attributable to HPV by site, country and HPV type. Int J Cancer. 2017;141(4):664–70. pmid:28369882
- 6. Konno R, Tamura S, Dobbelaere K, Yoshikawa H. Prevalence and type distribution of human papillomavirus in healthy Japanese women aged 20 to 25 years old enrolled in a clinical study. Cancer Sci. 2011;102(4):877–82. pmid:21251162
- 7. Zhao F-H, Zhu F-C, Chen W, Li J, Hu Y-M, Hong Y, et al. Baseline prevalence and type distribution of human papillomavirus in healthy Chinese women aged 18-25 years enrolled in a clinical trial. Int J Cancer. 2014;135(11):2604–11. pmid:24740547
- 8. Phongsavan K, Gustavsson I, Marions L, Phengsavanh A, Wahlstrom R, Gyllensten U. Detection of Human Papillomavirus Among Women in Laos. International Journal of Gynecological Cancer. 2012;22(8):1398–406.
- 9. Otero-Motta AP, Ordóñez JL, González-Celador R, Rivas B, Macías MDCG, Bullón A, et al. Prevalence of human papillomavirus genotypes in cytologic abnormalities from unvaccinated women living in north-western Spain. APMIS. 2011;119(3):204–15. pmid:21284738
- 10. Desai S, Chapman R, Jit M, Nichols T, Borrow R, Wilding M, et al. Prevalence of human papillomavirus antibodies in males and females in England. Sex Transm Dis. 2011;38(7):622–9. pmid:21317688
- 11. Carr KC, Sellors JW. Cervical cancer screening in low resource settings using visual inspection with acetic acid. J Midwifery Womens Health. 2004;49(4):329–37. pmid:15236713
- 12. Namale G, Mayanja Y, Kamacooko O, Bagiire D, Ssali A, Seeley J, et al. Visual inspection with acetic acid (VIA) positivity among female sex workers: a cross-sectional study highlighting one-year experiences in early detection of pre-cancerous and cancerous cervical lesions in Kampala, Uganda. Infect Agent Cancer. 2021;16(1):31. pmid:33975633
- 13. Mayrand M-H, Duarte-Franco E, Rodrigues I, Walter SD, Hanley J, Ferenczy A, et al. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med. 2007;357(16):1579–88. pmid:17942871
- 14. Arbyn M, Bergeron C, Klinkhamer P, Martin-Hirsch P, Siebers AG, Bulten J. Liquid Compared With Conventional Cervical Cytology. Obstet Gynecol. 2008;111:167–77.
- 15. Singh U, Anjum , Qureshi S, Negi N, Singh N, Goel M, et al. Comparative study between liquid-based cytology & conventional Pap smear for cytological follow up of treated patients of cancer cervix. Indian J Med Res. 2018;147(3):263–7. pmid:29923515
- 16.
Bruni L, Albero G, Serrano B, Mena M, Collado J, Gómez D. Human Papillomavirus and Related Diseases in Lao People’s Democratic Republic. 2017.
- 17. Ebrahimi N, Yousefi Z, Khosravi G, Malayeri FE, Golabi M, Askarzadeh M, et al. Human papillomavirus vaccination in low- and middle-income countries: progression, barriers, and future prospective. Front Immunol. 2023;14:1150238. pmid:37261366
- 18. Phongsavan K, Phengsavanh A, Wahlström R, Marions L. Women’s perception of cervical cancer and its prevention in rural Laos. Int J Gynecol Cancer. 2010;20(5):821–6. pmid:20606529
- 19. Takamatsu R, Nabandith V, Pholsena V, Mounthisone P, Nakasone K, Ohtake K, et al. Cervical cytology and human papillomavirus among asymptomatic healthy volunteers in Vientiane, Lao PDR. BMC Cancer. 2017;17(1):872. pmid:29258466
- 20. Sathawane P, Kamal MM, Deotale PR, Mankar H. Nuances of the Papanicolaou stain. Cytojournal. 2022;19:43. pmid:35928529
- 21. Nance KV. Diagnostic sensitivity for invasive cervical carcinoma of high risk HPV tests performed on SurePath™ liquid-based pap specimens. Drug Healthc Patient Saf. 2013;5:101–4. pmid:23580399
- 22. Solomon D, Davey D, Kurman R, Moriarty A, O’Connor D, Prey M, et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA. 2002;287(16):2114–9. pmid:11966386
- 23.
QIAGEN. QIAamp DNA Stool Handbook: For DNA purification from stool samples. Hilden, Germany: QIAGEN. 2012.
- 24. de Roda Husman AM, Walboomers JM, van den Brule AJ, Meijer CJ, Snijders PJ. The use of general primers GP5 and GP6 elongated at their 3’ ends with adjacent highly conserved sequences improves human papillomavirus detection by PCR. J Gen Virol. 1995;76 (Pt 4):1057–62. pmid:9049358
- 25. Cenci M, Rossi F, Pisani T. Detection of 14 High-risk Human Papillomavirus (HPV) Genotypes Within the Italian Cervical Cancer Screening. In Vivo. 2023;37(5):2161–5. pmid:37652482
- 26. Chan PKS, Ho WCS, Chan MCW, Wong MCS, Yeung ACM, Chor JSY, et al. Meta-analysis on prevalence and attribution of human papillomavirus types 52 and 58 in cervical neoplasia worldwide. PLoS One. 2014;9(9):e107573. pmid:25229350
- 27. Negri G, Rigo B, Vittadello F, Mian C, Egarter-Vigl E. Abnormal cervicovaginal cytology with negative human papillomavirus testing. Cancer. 2007;111(5):280–4. pmid:17724678
- 28. da Silva MC, Martins HPR, de Souza JL, Tognim MCB, Svidzinski TIE, Teixeira JJV, et al. Prevalence of HPV infection and genotypes in women with normal cervical cytology in the state of Paraná, Brazil. Arch Gynecol Obstet. 2012;286(4):1015–22. pmid:22699514
- 29. Asciutto KC, Borgfeldt C, Forslund O. 14-type HPV mRNA test in triage of HPV DNA-positive postmenopausal women with normal cytology. BMC Cancer. 2020;20(1):1025. pmid:33097006
- 30. Cakmak B, Köseoğlu DR. Comparison of cervical cytological screening results between postmenopausal and elderly women. Turk Patoloji Derg. 2014;30(1):38–42. pmid:24448705
- 31. Kovacic MB, Castle PE, Herrero R, Schiffman M, Sherman ME, Wacholder S, et al. Relationships of human papillomavirus type, qualitative viral load, and age with cytologic abnormality. Cancer Res. 2006;66(20):10112–9. pmid:17047075
- 32. Leong C, Takada JI, Yamaguchi S. Analysis of the changing landscape of a world heritage site: Case of Luang Prabang, Lao PDR. Multidisciplinary Digital Publishing Institute. 2016;8:1–23.
- 33.
Oudomxay: The Heart of Northern Laos. https://wearelao.com/menu-pages/oudomxay-the-heart-of-northern-laos/
- 34.
UNICEF. Lao social indicator survey III (LSIS III). 2026. https://www.unicef.org/laos/reports/lao-social-indicator-survey-iii-lsis-iii

관련 뉴스